On the 7th, the domestic stock market showed simultaneous weakness in both the KOSPI and KOSDAQ, and Kolon TissueGene is also struggling to avoid a sharp decline.

As of 11:07 a.m. on the 7th, Kolon TissueGene is trading at 16,560 won, down 1,010 won (5.75%) from the previous trading day. Trading volume has reached 1,342,481 shares. The stock price initially rose to 18,220 won early in the session but soon lost all of its gains and turned negative.

With both the KOSPI and KOSDAQ declining today, growth stocks and biotech stocks overall are under pressure. In particular, Kolon TissueGene has recently experienced large price swings, and coupled with the broader index decline, investor caution has heightened further.

Kolon TissueGene has previously exhibited high volatility, including sharp rebounds following steep declines. Therefore, it is necessary to assess whether this decline is simply a reflection of broader market weakness or the combined result of uncertainty over clinical outcomes and profit-taking following a recent short-term rebound.

The stock is now on a downward trend for the second consecutive session after rising for four straight trading days. This is a time to closely monitor market trends.

[This article was written based on intraday market prices, and stock prices may fluctuate in real time. Investment decisions and responsibilities lie with the investor. This article was written with AI assistance.]